| case report | Q2782326 |
| scholarly article | Q13442814 |
| P2093 | author name string | Morton Coleman | |
| Zaid H Tafesh | |||
| Jerry Nagler | |||
| Clifton Fulmer | |||
| P2860 | cites work | Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience | Q26738946 |
| Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase | Q27026912 | ||
| Ibrutinib in previously treated Waldenström's macroglobulinemia. | Q27853148 | ||
| Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury | Q28077505 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Hepatotoxicity of targeted therapy for cancer. | Q30250288 | ||
| Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results | Q30279207 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives | Q38101884 | ||
| A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib | Q38271453 | ||
| Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | Q39028378 | ||
| Ibrutinib-induced severe liver injury. | Q41811786 | ||
| Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach | Q42368314 | ||
| Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia | Q47424531 | ||
| Ibrutinib-induced acute liver failure. | Q48150752 | ||
| Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia | Q86969792 | ||
| P433 | issue | 2 | |
| P921 | main subject | ibrutinib | Q5984881 |
| P304 | page(s) | 357-363 | |
| P577 | publication date | 2019-05-01 | |
| P1433 | published in | Case reports in gastroenterology | Q27722663 |
| P1476 | title | Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases | |
| P478 | volume | 13 |
Search more.